- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01180049
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Kogarah, New South Wales, Australien, 2217
- St George Hospital
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Royal Adelaide Hospital
-
-
Tasmania
-
Hobart, Tasmania, Australien, 7000
- Royal Hobart Hospital
-
-
Victoria
-
Box Hill, Victoria, Australien, 3128
- Box Hill Hospital
-
Melbourne, Victoria, Australien, 3004
- The Alfred Hospital
-
-
-
-
-
Kazan, Den Russiske Føderation, 420029
- Republican Clinical Oncology Dispensary of the Ministry of Healthcare of Tatarstan Republic
-
Saint-Petersburg, Den Russiske Føderation, 197022
- GBOU VPO "First Saint-Petersburg State Medical University n.a. I.P.Pavlov"
-
Saint-Petersburg, Den Russiske Føderation, 197022
- Institute of Pediatric Hematology and Transplantology R.M.Gorbacheva
-
-
-
-
Florida
-
Miami, Florida, Forenede Stater, 33133
- Mercy Research Institute
-
-
New Jersey
-
East Orange, New Jersey, Forenede Stater, 07018
- Veterans Affairs New Jersey Healthcare System-Hematology/Oncology Section (111)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73120
- Mercy Clinic Oklahoma Communities dba Mercy Clinic Oncology/Hematology-McAuley
-
Oklahoma City, Oklahoma, Forenede Stater, 73120
- Mercy Hospital Oklahoma City-Oncology Infusion
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98108
- VA Puget Sound Health Care System
-
Seattle, Washington, Forenede Stater, 98108
- Amy Shen, RPh
-
-
-
-
-
Vandoeuvre les Nancy, Frankrig, 54500
- CHU de Nancy
-
-
-
-
-
Catania, Italien, 95124
- Presidio Ferrarotto - A.O.U. - PoliclinicoVittorio Emanuele
-
Modena, Italien, 41124
- Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica
-
Torino, Italien, 10126
- Struttura Complessa di Ematologia, Dipartimento di Oncologia ed Ematologia-
-
-
-
-
-
Seoul, Korea, Republikken, 135-710
- Samsung Medical Center
-
Seoul, Korea, Republikken, 120-752
- Severance Hospital, Yonsei University
-
-
-
-
-
Krakow, Polen, 30-510
- Malopolskie Centrum Medyczne s.c.
-
-
-
-
-
Bucuresti, Rumænien, 030171
- Spitalul Clinic Coltea, Clinica de Hematologie
-
Bucuresti, Rumænien, 022328
- Institutul Clinic Fundeni Bucuresti, Sectia II Hematologie
-
Bucuresti, Rumænien, 050098
- Spitalul Universitar de Urgenta Bucuresti, Clinica de Hematologie
-
-
-
-
-
Belgrade, Serbien, 11000
- Clinical Centre of Serbia,Clinic for Hematology
-
Sremska Kamenica, Serbien, 21204
- Oncology Institute of Vojvodina
-
-
-
-
-
Praha 10, Tjekkiet, 100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Praha 2, Tjekkiet, 128 08
- Vseobecna Fakultni Nemocnice V Praze
-
-
Czech Republic
-
Praha 10, Czech Republic, Tjekkiet, 10034
- Fakultni nemocnice Kralovske Vinohrady
-
-
-
-
-
Aachen, Tyskland, 52074
- Klinik fuer Onkologie und Haematologie, Medizinische Klinik IV
-
Mainz, Tyskland, 55131
- Klinikum Johannes-Gutenberg -Universitaet, III. Medizinische Klinik und Poliklinik
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Have confirmed mantle cell lymphoma diagnosis.
- Have measurable disease.
- Have received at least 2 prior treatment, which may include stem cell transplant.
- Have adequate organ and bone marrow function.
- There are other criteria--please discuss with your doctor.
Exclusion Criteria:
- Had any prior treatment with temsirolimus or mTOR inhibitor.
- Had allogeneic stem cell transplant within last 6 months and on immunosuppressive therapy.
- Has active or untreated brain or central nervous system metastases.
- There are other criteria--please discuss with your doctor.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: temsirolimus (Torisel) 175mg weekly x 3, then 75mg weekly
|
175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
Andre navne:
75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
Andre navne:
|
Aktiv komparator: temsirolimus (Torisel) 75mg weekly
|
175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
Andre navne:
75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Independently Assessed Progression-free Survival (PFS)
Tidsramme: From randomization date to the date of first documentation of progression or death (average follow up done for 15 months)
|
PFS is defined as the time from randomization to first documentation of disease progression by the independent assessor or to death due to any cause, whichever occurred first. PFS = (earliest date of progression or death due to any cause- randomization date+1)/30.4. PFS assessment was done using EMA guidelines for sensitivity analysis censoring. Participants who were alive and progression-free at the time of analysis were censored on the date of last assessment; participants without adequate baseline assessment or without post-baseline assessments were censored on the randomization date; participants who died or progressed after 2 or more missed visits were censored on the date of last tumor assessment prior to the missing visit; and participants who started new anti-cancer therapy prior to death or progression were censored on the date of last tumor assessment prior to the start of anti-tumor treatment. |
From randomization date to the date of first documentation of progression or death (average follow up done for 15 months)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall Survival (OS)
Tidsramme: From randomization date until death due to any cause (average follow up done for 56.1 months)
|
OS is defined as the time from the date of randomization to the date of death due to any cause.
|
From randomization date until death due to any cause (average follow up done for 56.1 months)
|
Independent Assessment - Objective Response Rate (ORR = CR + PR)
Tidsramme: From randomization date until end of treatment (average follow up done for 15 months)
|
ORR is defined as the percentage of participants with confirmed CR or PR according to the Cheson Criteria relative to all randomized Participants. Tumor responses were determined using information from objective measurements from computed tomography information including B-symptom evaluation, physical examination, ECOG performance status, assessment of liver and spleen, laboratory assessments such as bone marrow biopsies and/or aspirates, biochemical markers of disease activity and hematology results. Participants who did not have on-study radiographic tumor re-evaluation or who died, progressed or dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the (CT) scans, as well as clinical assessment of ORR. |
From randomization date until end of treatment (average follow up done for 15 months)
|
Investigator's Assessment ORR (ORR = CR + PR)
Tidsramme: From randomization date until end of treatment (average follow up done for 15 months)
|
ORR is defined as the percentage of participants with confirmed CR or PR according to the Cheson Criteria relative to all randomized Participants. Tumor responses were determined using information from objective measurements from computed tomography information including B-symptom evaluation, physical examination, ECOG performance status, assessment of liver and spleen, laboratory assessments such as bone marrow biopsies and/or aspirates, biochemical markers of disease activity and hematology results. Participants who did not have on-study radiographic tumor re-evaluation or who died, progressed or dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the (CT) scans, as well as clinical assessment of ORR. |
From randomization date until end of treatment (average follow up done for 15 months)
|
Investigator Assessed PFS
Tidsramme: From randomization date to the date of first documentation of progression or death (average follow up done for 15 months)
|
PFS is defined as the time from randomization to first documentation of disease progression by the independent assessor or to death due to any cause, whichever occurred first. PFS = (earliest date of progression or death due to any cause- randomization date+1)/30.4. PFS assessment was done using EMA guidelines for sensitivity analysis censoring. Participants who were alive and progression-free at the time of analysis were censored on the date of last assessment; participants without adequate baseline assessment or without post-baseline assessments were censored on the randomization date; participants who died or progressed after 2 or more missed visits were censored on the date of last tumor assessment prior to the missing visit; and participants who started new anti-cancer therapy prior to death or progression were censored on the date of last tumor assessment prior to the start of anti-tumor treatment. |
From randomization date to the date of first documentation of progression or death (average follow up done for 15 months)
|
Percentage of Participants With Treatment-Emergent Infection- Related Adverse Events (AEs) With Grade 2 or Higher as Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Tidsramme: From screening up to a maximum of 57.1 months
|
An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.
Treatment emergent adverse event=as an event that emerged during treatment period that was absent before treatment, or worsened during treatment period relative to pretreatment state.
Treatment-emergent infection-related AEs included events: pneumonia, bronchitis, infection, herpes simplex, oral candidiasis and sepsis.
Grading by NCI CTCAE Version 3.0.: Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening; urgent intervention indicated; Grade 5= death.
|
From screening up to a maximum of 57.1 months
|
Percentage of Participants With Treatment-Emergent Bleeding-Related AEs With Grade 2 or Higher as Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Tidsramme: From screening up to a maximum of 57.1 months
|
An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.
Treatment emergent adverse event=as an event that emerged during treatment period that was absent before treatment, or worsened during treatment period relative to pretreatment state.
Treatment-emergent bleeding related AEs included events: epistaxis and ecchymosis.
AE were assessed according to maximum severity grading based on NCI CTCAE Version 4.03.Grade 1=mild; Grade 2=moderate; within normal limits.
Grade 3=severe or medically significant but not immediately life-threatening; Grade 4=life-threatening or disabling; urgent intervention indicated; Grade 5=death.
|
From screening up to a maximum of 57.1 months
|
Quantify the Potential Effect of TEMSR on AUC and Cmax
Tidsramme: From one week predose (Day -7, -4hr, -8hr, -48hr) upto 2 weeks post dose (4hr, 8hr, 48hr and Day 8)
|
Potential TEMSR effects were investigated by calculating the ratio of AUCs with and without concomitant TEMSR from the model-estimated effect of TEMSR on apparent clearance (CL/F) values and using individual ratios of observed Cmax values with and without concomitant temsirolimus, for both parent and metabolite. The AUC mean ratio was calculated as 1 / mean shift on apparent clearance from TEMSR, and the 90% CI of the AUC ratios was calculated as 1 / 90% CI of the shift on apparent clearance from TEMSR. AUC: Area under plasma concentration-time curve from time zero to infinity Cmax: Characterization of maximum observed plasma concentration |
From one week predose (Day -7, -4hr, -8hr, -48hr) upto 2 weeks post dose (4hr, 8hr, 48hr and Day 8)
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- Lymfom
- Lymfom, Non-Hodgkin
- Lymfom, kappecelle
- Lægemidlers fysiologiske virkninger
- Anti-infektionsmidler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antibakterielle midler
- Antibiotika, antineoplastisk
- Antifungale midler
- Sirolimus
Andre undersøgelses-id-numre
- 3066K1-4438
- B1771007 (Anden identifikator: Alias Study Number)
- 2009-015498-11 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Non-Hodgkins lymfom
-
Marker Therapeutics, Inc.RekrutteringNon Hodgkin lymfom | Non-Hodgkin lymfom, voksen | Non-Hodgkin lymfom, refraktær | Non-Hodgkin lymfom, tilbagefaldForenede Stater
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Ikke rekrutterer endnuLymfom | Lymfom, Non-Hodgkin | Non-Hodgkins lymfom | Non-Hodgkin lymfom | Refraktær B-celle non-Hodgkin lymfom | Refraktær non-Hodgkin lymfom | Højgradigt B-celle lymfom | CNS lymfom | Lymfomer Non-Hodgkins B-celle | Recidiverende non-Hodgkin lymfom | Lymfom, Non-Hodgkins | Stort B-celle lymfom | Lymfom, Non-Hodgkins... og andre forhold
-
Stanford UniversityNational Institutes of Health (NIH); AmgenAfsluttetLymfom, Non-Hodgkin | Lymfomer: Non-Hodgkin | Lymfomer: Non-Hodgkin perifer T-celle | Lymfomer: Non-Hodgkin kutan lymfom | Lymfomer: Non-Hodgkin diffuse store B-celler | Lymfomer: Non-Hodgkin follikulært / indolent B-celle | Lymfomer: Non-Hodgkin kappecelle | Lymfomer: Non-Hodgkin Marginal Zone | Lymfomer...Forenede Stater
-
Caribou Biosciences, Inc.RekrutteringLymfom | Lymfom, Non-Hodgkin | B-celle lymfom | Non Hodgkin lymfom | Refraktær B-celle non-Hodgkin lymfom | Recidiverende non-hodgkin lymfom | B-celle non-Hodgkins lymfomForenede Stater, Australien, Israel
-
Chongqing Precision Biotech Co., LtdRekrutteringNon Hodgkin lymfom | Refraktær non-Hodgkin lymfom | Recidiverende non-Hodgkin lymfomKina
-
Memorial Sloan Kettering Cancer CenterRekrutteringNon-Hodgkin lymfom | Non-Hodgkins lymfom, tilbagefald | Non-Hodgkins lymfom refraktærForenede Stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringRefraktær B-celle non-Hodgkin lymfom | Tilbagevendende B-celle non-Hodgkin lymfom | Højgradig B-celle non-Hodgkins lymfom | Mellemklasse B-celle non-Hodgkins lymfomForenede Stater
-
Mayo ClinicIkke rekrutterer endnuIndolent B-celle non-Hodgkin lymfom | Tilbagevendende indolent non-Hodgkin-lymfom | Refraktært indolent non-Hodgkin lymfom | Tilbagevendende indolent B-celle non-Hodgkin lymfom | Refraktært indolent B-celle non-Hodgkin lymfomForenede Stater
-
National Cancer Institute (NCI)RekrutteringRefraktær B-celle non-Hodgkin lymfom | Refraktær T-celle non-Hodgkin lymfom | Tilbagevendende B-celle non-Hodgkin lymfom | Tilbagevendende transformeret non-Hodgkin-lymfom | Tilbagevendende non-Hodgkin-lymfom | Refraktær non-Hodgkin lymfom | Tilbagevendende T-celle non-Hodgkin lymfom | Tilbagevendende... og andre forholdForenede Stater
-
SIRPant Immunotherapeutics, Inc.RekrutteringRefraktær non-Hodgkin lymfom | Recidiverende non-Hodgkin lymfomForenede Stater
Kliniske forsøg med temsirolimus
-
Sheba Medical CenterStanley Medical Research InstituteUkendtSkizofreni | Skizoaffektiv lidelseIsrael
-
St. Joseph's Healthcare HamiltonPfizer; McMaster UniversityAfsluttet
-
New Mexico Cancer Care AllianceWyeth is now a wholly owned subsidiary of PfizerAfsluttetSarkomForenede Stater
-
AVEO Pharmaceuticals, Inc.Afsluttet
-
Dana-Farber Cancer InstituteWyeth is now a wholly owned subsidiary of Pfizer; Millennium Pharmaceuticals...Afsluttet
-
Children's Hospital Medical Center, CincinnatiTrukket tilbageLymfom, B-celle | Leukæmi, B-celleForenede Stater
-
Goethe UniversityAfsluttetAkut myeloblastisk leukæmiTyskland
-
Mathias Witzens-HarigCharite University, Berlin, Germany; Ludwig-Maximilians - University of... og andre samarbejdspartnereUkendtDiffust storcellet B-celle lymfomTyskland
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerAfsluttetBrystneoplasmer
-
M.D. Anderson Cancer CenterAfsluttet